KAKEN PHARMACEUTICAL CO., LTD.
4521・Prime Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. Composed of 8 directors (of which 3 are outside directors) and 4 corporate auditors (of which 2 are outside corporate auditors). The Board of Directors met 19 times during the fiscal year under review, with all directors attending every meeting. The company has introduced an executive officer system to accelerate decision-making and clarify the separation of oversight and business execution functions.
Risk Management
The Company has established a Risk Management Committee, chaired by the officer in charge of risk management, based on its Risk Management Regulations, and implements risk management on a company-wide basis. For sustainability-related risks, the Sustainability Committee conducts detailed reviews, and a framework has been put in place whereby important matters are submitted to and reported to the Board of Directors.
Shareholder Returns
Basic policy is to pay dividends twice a year, and for FY2026 (ending March 2026), an annual dividend of ¥190 (interim ¥95 + year-end ¥95) is being implemented. Payout ratio is 335.9%. An annual dividend of ¥190 is also forecast for FY2027 (ending March 2027). The company conducted a share buyback (538,800 shares; ¥2,340 million) and retired 1,800,000 shares.
Dividend Policy
The basic policy is to pay dividends twice a year, comprising an interim dividend and a year-end dividend. For FY2026 (ending March 2026), an interim dividend of ¥95 and a year-end dividend of ¥95 are being implemented, for an annual total of ¥190 (total dividends of ¥7,232 million, payout ratio of 335.9%). In the previous fiscal year (FY2025, ended March 2025), the annual dividend was also ¥190 (interim ¥115 + year-end ¥75), which included a special dividend of ¥40; in the current fiscal year, the same total amount is being maintained through ordinary dividends only. An annual dividend of ¥190 (interim ¥95 + year-end ¥95) is also forecast for FY2027 (ending March 2027). Retained earnings will be invested primarily in R&D, overseas expansion, and strengthening the management foundation, with the aim of maximizing corporate value. Additionally, the partial revision of the 'Long-Term Management Plan 2031,' announced on April 8, 2025, explicitly states a strengthening of shareholder returns.
ESG
The company has set a target to reduce CO2 emissions by 51% in FY2030 compared to FY2016 levels, utilizing CO2-free electricity adoption and internal carbon pricing. In terms of human capital, the company manages KPIs across a variety of indicators, including a female manager ratio of 7.2% (achieving the FY2025 target of 7.0%), a male childcare leave utilization rate of 82.9%, and Certified Health and Productivity Management Organization recognition (for three consecutive years).
Last updated: June 25, 2026